Physicians’ experience, practice and education, on genetic testing and genetic counseling: a nationwide survey study in Greece
- 24 January 2022
- journal article
- research article
- Published by Springer Nature in Familial Cancer
- Vol. 21 (4) , 479-487
Abstract
Genetic testing has been implemented in clinical practice. However, data on physician’s practices and education related to cancer genetics, risk assessment and clinical management in Greece, is limited. In Greece, genetic counseling is performed by treating physicians in collaboration with clinical laboratory geneticists due to the absence of medical geneticists and genetic counsellors. We evaluated treating physicians’ experience on genetic testing for hereditary cancer and counseling practices in Greece, thus providing critical areas for improvement of genetic counseling processes. A 28-question survey was used to assess physicians’ experience with genetic testing practices, factors that affect their clinical management and decision making and limitations in their education. Of 250 physicians, 208 (83%) completed the survey; of whom 89 (42.8%) were medical oncologists, 88 general surgeons (42.3%), 26 gynecologists (12.5%) and 5 (2.4%) of other specialties. Overall, 91.8% of participants referred patients for genetic testing, with 51.8% recommending multigene panel testing. While most clinicians (84%) reported lack of a clinical genetics department at their institution, 75.7% referred patients for genetic counseling at available departments or healthcare professionals with expertise in genetic counseling. Overall, 68.8% of respondents reported no training or moderate training on cancer genetics. A higher proportion of medical oncologists reported sufficient/very satisfactory training (40.9%) compared to general surgeons (27.3%) or gynecologists (11.5%) (p = 0.012). Time spent on pre- and post-testing sessions varied significantly among respondents. Of 199 physicians, 70% would manage patients with BRCA1 VUS as patients with pathogenic variants, mainly surgeons (83.1%) and gynecologists (80%), compared to oncologists (52.3%) (p < 0.001). Additionally, 64% of physicians treating patients with breast and ovarian cancer would recommend an intervention based on the presence of a BRCA1 VUS. Most respondents (87%) were interested in receiving additional education on cancer risk assessment. Limited consensus was observed during physicians’ genetic testing, counseling practices and clinical management of patients with increased predisposition to cancer. Our findings highlight the need for improvement in physician education on cancer risk assessment and increase of genetic counseling resources and services.Keywords
This publication has 22 references indexed in Scilit:
- Clinical Evaluation of a Multiple-Gene Sequencing Panel for Hereditary Cancer Risk AssessmentJournal of Clinical Oncology, 2014
- Physicians' Attitudes About Multiplex Tumor Genomic TestingJournal of Clinical Oncology, 2014
- Educational Needs and Preferred Methods of Learning Among Florida Practitioners Who Order Genetic Testing for Hereditary Breast and Ovarian CancerJournal of Cancer Education, 2013
- A Statewide Survey of Practitioners to Assess Knowledge and Clinical Practices Regarding Hereditary Breast and Ovarian CancerGenetic Testing and Molecular Biomarkers, 2013
- Genetic testing and cancer risk management recommendations by physicians for at-risk relativesGenetics in Medicine, 2011
- Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencingProceedings of the National Academy of Sciences, 2010
- Cancer Genetic Risk Assessment and Referral Patterns in Primary CareGenetic Testing and Molecular Biomarkers, 2009
- The counsellees' view of an unclassified variant in BRCA1/2: recall, interpretation, and impact on lifePsycho-Oncology, 2008
- Hereditary breast/ovarian and colorectal cancer genetics knowledge in a national sample of US physiciansJournal of Medical Genetics, 2005
- Clinical Interpretation and Recommendations for Patients with a Variant of Uncertain Significance in BRCA1 or BRCA2 : A Survey of Genetic Counseling PracticeGenetic Testing, 2002